Application of reticulated platelets to transfusion management during autologous stem cell transplantation by Parco, Sergio & Vascotto, Fulvia
© 2012 Parco and Vascotto, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
OncoTargets and Therapy 2012:5 1–5
OncoTargets and Therapy
Application of reticulated platelets to transfusion 
management during autologous stem cell 
transplantation
Sergio Parco
Fulvia Vascotto
Institute for Maternal and Child 
Health – IRCCS Burlo Garofolo, 
Trieste, Italy
Correspondence: Sergio Parco 
Institute for Maternal and Child  
Health – IRCCS Burlo Garofolo,  
Via dell’Istria 65/1, 34137 Trieste, Italy 
Tel +39 0403785332 
Fax +39 0403785210 
Email parco@burlo.trieste.it
Background: The immature (or reticulated) platelet fraction (IPF) is rich in nucleic acids, 
especially RNA, and can be used as a predictive factor for platelet recovery in platelet 
  immunomediated consumption or in postchemotherapy myelosuppression. Our aim was to 
determine if transfusions with IPF-rich solutions, during autologous peripheral blood stem cell 
transplantation, reduce the occurrence of bleeding and hemorrhagic complications.
Patients and methods: Transfusions were administered to 40 children, affected with 
  hematological pathologies, who underwent autologous peripheral hematopoietic progenitor 
cell transplantation. There were two groups of 20 patients, one group treated with IPF-poor and 
the other with IPF-rich solutions. In the two groups, the conditioning regimen was the same 
for the same pathology (hematological pathologies: 14 acute lymphoblastic leukemia; twelve 
acute myelocytic leukemia; four non-Hodgkin’s lymphoma; two Hodgkin’s lymphoma; eight 
solid tumors). A new automated analyzer was used to quantify the IPF: the XE2100 (Sysmex, 
Kobe, Japan) blood cell counter with upgraded software.
Results: The 20 patients who received solutions with a high percentage of IPF (3%–9% 
of total number of infused platelets) required fewer transfusions than the 20 patients who 
received   transfusions with a low percentage of IPF (0%–1% of total number of infused 
platelets): 83 versus 129 (mean of number of transfusions 4.15 versus 6.45) and a significant 
  difference was found between the two groups by using the Mann–Whitney test (P , 0.001). 
The   prophylactic transfusions decreased from three to two per week. There was only one case 
of massive hemorrhage.
Conclusion: The use of IPF solutions reduces the number of transfusions and bleedings after 
peripheral blood stem cell transplantation in pediatric patients.
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Introduction
Immature (or reticulated) platelets (PLTs) contain more RNA than mature PLTs and 
their number in peripheral blood reflects the rate of thrombopoiesis. Immature PLTs 
are more active than nonreticulated PLTs because of their higher nucleic acid content 
and higher expression of P-selectin and glycoprotein. New automated, US Food and 
Drug Administration-approved methods have been developed to count immature 
PLTs.1–3 The immature PLT fraction (IPF) count is a useful index of thrombopoiesis, 
which increases when the IPF rises and decreases when the IPF declines.
The IPF count reflects peripheral PLT destruction that results from the suppression 
of bone marrow production and can be used as a predictive factor for PLT recovery 
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postchemotherapy myelosuppression or in PLT immunomedi-
ated consumption. IPF counts have been described as a better 
marker of PLT activity not only in thrombopoietic disorders, 
such as thrombotic thrombocytopenia purpura but also in 
various clinical conditions, such as hematopoietic stem cell 
transplantation, myelodysplasia, acute coronary syndrome, 
and in patients on hemodialysis.4–7
In this study, we tested the efficacy of transfusions in 
pediatric patients, who underwent autologous peripheral 
hematopoietic progenitor cell transplantation, with PLT 
concentrates (PCs) enriched with young and more active 
PLTs (IPF). We determined whether this treatment reduced 
the occurrence of massive or mucosal hemorrhage during 
the post-transplantation period.
The study design was to evaluate the relationship between 
two groups of transfusions, one with IPF-poor and the 
other with IPF-rich solutions stored for the same time and 
similarly administered in terms of transfusion frequency, and 
the development of hemorrhagic or transfusion-transmitted 
complications.8,9 We also aimed to verify the utility of a new 
automated hemoanalyzer to count the IPF in donors and in 
PCs and to study the outcome in patients.
Materials and methods
Over a 2-year period, two groups of 20 children (aged 5–18 
years) received transfusions with either IPF-poor solutions or 
with IPF-rich solutions, during autologous peripheral blood 
stem cell (PBSC) transplantation, according to the EU pro-
cedures,33 as reported in the manual for transfusions at our 
hospital. In the two groups, the conditioning regimen was the 
same for the same pathology (hematological pathologies: 14 
acute lymphoblastic leukemia, twelve acute myelocytic leu-
kemia (AML), four non-Hodgkin’s lymphoma, two Hodgkin’s 
lymphoma, eight solid tumors). Young patients were classified 
as follows: (1) stable and receiving prophylactic therapy, hav-
ing a PLT count , 10,000/µL; (2) having mucosal   hemorrhage 
with a PLT count , 50,000/µL; (3) exhibiting signs of active 
bleeding from insertion catheters with a PLT count between 
50,000 and 100,000/µL; (4) experiencing massive blood loss 
with a PLT count of , 50,000/µL. Before entering this study 
an informed consent form was delivered to all patients (or their 
parents), which was approved by the Ethics Committee of the 
Hospital; only one patient did not return the consent form.
The IPF is donor dependent (range in human blood: 0.3%–
7.0% of total PLT). The blood donors in our study were selected 
into two groups, one with an IPF range of 0.3%–3.5%, the other 
with a range of 3.6%–7.0%. To quantify the reticulated PLTs, 
we used a new automated instrument, the XE-2100 (Sysmex, 
Kobe, Japan), with a modern routine, fully automated analyzer 
and upgraded software.10 The thrombelastograph (Medival, 
Padua, Italy) was implemented to aid in the treatment of 
possible coagulopathy. We used the Procleix Ultrio (Chiron 
Ltd, Emeryville, CA) test kit-based transcription-mediated 
amplification for nucleic acid amplification testing studies 
of serum samples from donors (human immunodeficiency 
virus, hepatitis C virus, and hepatitis B virus). Otherwise, 
a microenzyme-linked immunosorbent assay was used in 
parallel for routine serological screening of anti-human 
immunodeficiency virus, anti-hepatitis C virus and HBsAg 
antibodies (Roche, Milan, Italy). For the syphilis test we used 
a chemiluminescence method (Abbott, Milan, Italy).
The PLT apheresis procedures were performed using 
healthy volunteer donors according to European   regulations. 
A blood cell separator (Haemonetics MCS Plus version C, 
Haemonetics Corp, Baintree, MA) was used, with multi-
component collection kits. After collecting standard PLT, 
the separator was adjusted to collect PLT cyclically. Cycle 
numbers and volumes were adjusted in the processor to   collect 
an average of 3.0 × 1011 (±0.5) PLTs according to the donors’ 
weight and height. Before the plasma reinfusion phase, PLTs 
Table 1   Data  for  immature  platelet  fraction-administered 
concentrates (ABO compatible)
Total  
numbers
Whole dose  
(3 ± 0.2 × 1011)
Half dose  
(1.5 ± 0.2 × 1011)
IPF-poor 129 81 48
IPF-rich 83 52 31
Abbreviation: ABO, blood groups A, B, AB, and O.
Table 2 Use of immature platelet fraction–rich solutions during post-cell transplant period in categories with platelet count ,10,000/µL 
(prophylactic therapy) and ,50,000/µL (mucosal hemorrhage)
Patients 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Number of transfusions 4 4 4 4 6 4 4 4 4 4 4 5 4 4 4 4 4 4 4 4
Massive hemorrhages 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mucosal hemorrhages 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Number of infections 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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harvested were sent to a dry PC bag, withdrawn by a syringe, 
and counted with the XE-2100 analyzer. The contents of the 
separation chamber were then driven into the standard PC bag, 
to avoid plasma contamination, and then into a PC bag con-
taining additive storage solution (T-SOL; Baxter, Deerfield, 
IL). After collection, both plasma PC and PC with T-SOL 
were left undisturbed for 1 hour. For sampling, the plasma PC 
was connected to a 100 mL transfer bag using a sterile con-
nection system and approximately 15 mL was withdrawn for 
analysis. The other bag contained a mean of 3.0 (±0.2) × 1011 
PLTs, and was preserved in T-SOL at 23°C for no longer than 
2 days to avoid changes of numbers over time.11 The PCs were 
leukodepleted by MachoPharma filters (Mouvaux, France) 
to avoid immunologically mediated effects, further possible 
bacterial contaminations, and infectious disease transmission 
(cytomegalovirus, human T-lymphotrophic virus Type I and 
II).12–14 Finally, they were also treated by a gamma irradiator 
for 6 minutes, at the time of transfusion.16,17 The treatment 
and checking of the two groups were similar. Physicians and 
patients understood and approved the treatment with IPF. The 
data were analyzed using a nonparametric statistical test and 
the Mann–Whitney test in order to overcome the underly-
ing assumption of normality in parametrics tests with small 
sample and because the two samples under consideration 
may not necessarily have the same number of observations. 
The conditions of the patients were stabilized about the main 
parameters (stable Hb; normal coagulation tests; general 
satisfactory health without fever, cough or infections).
Results
In this report only the first two categories, PLT count , 10,000/µL   
(prophylactic therapy) and PLT count , 50,000 (mucosal 
hemorrhage), were evaluated, for a total number of 40 patients. 
Twenty received transfusions of 3.0 × 1011 PLTs with a low 
IPF level (0%–1% of total infused PLTs) and the other 20 
received IPF-rich transfusions (3%–9% of total infused PLTs). 
The dose of infused IPF was different, in accordance with the 
patient’s weight: 3.0 (±0.2) for children of 40–60 kg; 1.5 (±0.2) 
for children of 20–39 kg (Table 1). In this second case, the 
remaining half dose of IPF was used to prepare heterologous 
PLT gel to cure skin ulcers, sores, and bone degeneration in 
other patients.
The data show that the efficacy of transfusion in the 
20 patients who received rich IPF was higher than that of 
low IPF transfusion (Tables 2 and 3). There was only one 
case of massive blood loss post-transplantation versus three 
in the low IPF group and no cases of mucosal hemorrhage. 
The number of transfusions was lower for patients receiving 
rich IPF than low IPF solutions and the rich IPF decreased 
the need for prophylactic transfusions from three to two 
per week (Figure 1). The timing of engraftment and patient 
outcome were the same (mean of 10 days ± 3) for patients 
Table 3 Use of immature platelet fraction–poor solutions during post-cell transplant period in categories with platelet count , 
10,000/µL (prophylactic therapy) and ,50,000/µL (mucosal hemorrhage)
Patients 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Number of transfusions 6 6 7 6 6 6 8 6 6 7 6 6 6 8 6 6 8 6 6 7
Massive hemorrhages 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 1 0 0 0
Mucosal hemorrhages 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1
Number of infections 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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Figure 1 (A) Use of IPF during post stem cells transplant period. (B) Massive or mucosal hemorrhagic complications during post stem cells transplant period.
Abbreviation: IPF, immature platelet fraction.
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receiving autograft transplants, and there were no cases of 
hemorrhage, bacterial contamination due to management 
and counting of IPF, transfusion-transmitted infections, or 
other health-related complications.18–23 We used the Mann–
Whitney test to compare the number of transfusions between 
the two groups of patients and pathologies (because it is a 
nonparametric statistical test), and a significant difference 
was observed (Table 4). The initial health conditions before 
transplantation were similar, including stable hemoglobin 
values, normal coagulation tests, and general satisfactory 
health.
Conclusion
The exclusion and inclusion criteria of the study excluded 
only three cases (fever and cough) and one IPF transfusion 
(PLT clumps in the bag), as European Bone Marrow Trans-
plantation criteria prescribe for a trial.34 The processing time 
to control IPF dosage was relatively short (5 minutes) and did 
not affect the cost of the procedure. This counting is essential 
during the last cycle of PLT apheresis, to determine whether 
the collected plasma has a high percentage of reticulated PLTs 
for clinical use; if it does not, another cycle is programmed. 
No viral or bacterial infections due to donors, management 
of transfusions, or IPF dosage were observed.24,25
In our experience it seems beneficial to use IPF-enriched 
solutions to transfuse children with complex pathologies, 
such as during PBSC transplantation, and the IPF transfu-
sions are essential for reducing the incidence of hemorrhagic 
complications. It is necessary to select blood donors with a 
high percentage of IPF (3.6%–7.0% of total PLT).
IPF transfusion needs further investigation to establish the 
social and economic cost, but the benefits of using IPF solu-
tions include reduction in the severity of hematologic disease 
and related complications, such as intravascular coagulation 
during PBSC transplantation in children and young patients, 
and the frequency of minor side effects including mucosal 
hemorrhage.26–29 The higher cost to carry out “dedicated” 
PLT apheresis and the purchase of a modern hemocytometer 
for quantifying the IPF, is offset by the savings in health and 
medical support for post-transplantation complications. 
Laboratory and clinical investigations of the functionality of 
reticulated PLTs in hemostasis, compared to mature PLTs, 
encouraged these studies.30–32
It is critical also to choose the dosage and the use of IPF 
as a prophylactic approach to lower the chances of post-
transplantation bleeding, especially in high-risk cases. To 
collect and determine the dosage of the IPF by PLT aphere-
sis, a standardized procedure is essential. The next step in 
the refinement of this methodology is the integrated output, 
which comprises a value that indicates the blood volume of 
selected donors that must be processed to obtain the desired 
PLT number and IPF. It involves the creation of a registry 
of “dedicated” donors.
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